NCT02583412View on ClinicalTrials.gov

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

June 30, 2017

Conditions
Meningococcal Serogroup B
Interventions
BIOLOGICAL

Bexsero®

Multicomponent meningococcal B vaccine

BIOLOGICAL

Havrix®

Hepatitis A vaccine

Trial Locations (1)

B3K 6R8

IWK Health Centre, Halifax

All Listed Sponsors
collaborator

University of British Columbia

OTHER

collaborator

University of Calgary

OTHER

collaborator

Université de Montréal

OTHER

collaborator

Dalhousie University

OTHER

lead

Canadian Immunization Research Network

NETWORK

NCT02583412 - Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults | Biotech Hunter | Biotech Hunter